Giovanni Paganelli, MD
IRST IRCCS · IRST IRCCS, Meldola (FC)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Giovanni Paganelli, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:58 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05208229 · The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · terminated · Metastatic Castration Resistant Prostate Cancer (mCRPC) · study chair
- Ph2NCT02736448 · 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · terminated · Gastro-entero-pancreatic Neuroendocrine Tumors · study chair
- Ph1/Ph2NCT02736500 · Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine TumorsIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · completed · Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.